Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics, retaining the price target of $20.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors tied to the early but strengthening launch of ZEVASKYN and its attractive economics. He highlights that the therapy is gaining real-world momentum in treating recessive dystrophic epidermolysis bullosa, supported by rising patient identification, a growing pipeline of biopsies in manufacturing, and an expanding network of Qualified Treatment Centers, all underpinned by a high per‑patient price and minimal reimbursement frictions.
He also points to the sizable U.S. patient pool relative to his conservative penetration assumptions, suggesting meaningful upside to long‑term revenue potential. Stronger‑than‑expected 2025 sales, higher updated revenue projections for 2026, and the view that Abeona can reach cash flow positivity by 2027 reinforce his conviction that the current valuation does not fully reflect the company’s growth prospects, justifying a Buy rating and a $20 twelve‑month price target.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $17.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABEO in relation to earlier this year.